Cargando…

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenici...

Descripción completa

Detalles Bibliográficos
Autores principales: Yegorov, Sergey, Kadyrova, Irina, Negmetzhanov, Baurzhan, Kolesnikova, Yevgeniya, Kolesnichenko, Svetlana, Korshukov, Ilya, Baiken, Yeldar, Matkarimov, Bakhyt, Miller, Matthew S., Hortelano, Gonzalo H., Babenko, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342835/
https://www.ncbi.nlm.nih.gov/pubmed/35915123
http://dx.doi.org/10.1038/s41598-022-17514-3
_version_ 1784760905533227008
author Yegorov, Sergey
Kadyrova, Irina
Negmetzhanov, Baurzhan
Kolesnikova, Yevgeniya
Kolesnichenko, Svetlana
Korshukov, Ilya
Baiken, Yeldar
Matkarimov, Bakhyt
Miller, Matthew S.
Hortelano, Gonzalo H.
Babenko, Dmitriy
author_facet Yegorov, Sergey
Kadyrova, Irina
Negmetzhanov, Baurzhan
Kolesnikova, Yevgeniya
Kolesnichenko, Svetlana
Korshukov, Ilya
Baiken, Yeldar
Matkarimov, Bakhyt
Miller, Matthew S.
Hortelano, Gonzalo H.
Babenko, Dmitriy
author_sort Yegorov, Sergey
collection PubMed
description Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID-19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine’s effects on systemic immunology.
format Online
Article
Text
id pubmed-9342835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-93428352022-08-02 Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study Yegorov, Sergey Kadyrova, Irina Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Baiken, Yeldar Matkarimov, Bakhyt Miller, Matthew S. Hortelano, Gonzalo H. Babenko, Dmitriy Sci Rep Article Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID-19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine’s effects on systemic immunology. Nature Publishing Group UK 2022-08-01 /pmc/articles/PMC9342835/ /pubmed/35915123 http://dx.doi.org/10.1038/s41598-022-17514-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yegorov, Sergey
Kadyrova, Irina
Negmetzhanov, Baurzhan
Kolesnikova, Yevgeniya
Kolesnichenko, Svetlana
Korshukov, Ilya
Baiken, Yeldar
Matkarimov, Bakhyt
Miller, Matthew S.
Hortelano, Gonzalo H.
Babenko, Dmitriy
Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
title Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
title_full Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
title_fullStr Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
title_full_unstemmed Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
title_short Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
title_sort sputnik-v reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342835/
https://www.ncbi.nlm.nih.gov/pubmed/35915123
http://dx.doi.org/10.1038/s41598-022-17514-3
work_keys_str_mv AT yegorovsergey sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT kadyrovairina sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT negmetzhanovbaurzhan sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT kolesnikovayevgeniya sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT kolesnichenkosvetlana sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT korshukovilya sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT baikenyeldar sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT matkarimovbakhyt sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT millermatthews sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT hortelanogonzaloh sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy
AT babenkodmitriy sputnikvreactogenicityandimmunogenicityinthebloodandmucosaaprospectivecohortstudy